Suzhou Alphamab

China antibody-engineering biotech (mAbs, fusion proteins, bispecifics) -- private parent entity distinct from the HKEX-listed spinout Alphamab Oncology (9966.HK)

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
PD-L1Monoclonal antibody
HIVNon-Small Cell Lung CancerChronic Hepatitis BEndometrial Cancer
Phase 1/2
Factor XI/XIa (FXI/FXIa)Monoclonal antibody
HypertensionChronic Kidney Disease

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
EnvafolimabPhase 1/2Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
Est. primary completion 2026-12 · NCT05024214 · CT.gov ↗
What to watch
EnvafolimabPhase 2Advanced Endometrial Cancer
Est. primary completion 2026-12 · NCT05112991 · CT.gov ↗
What to watch
2027 (3)
August 2027 (2)
KN060Phase 1/2End-Stage Renal Disease Requiring Haemodialysis
Est. primary completion 2027-08-15 · NCT07201467 · CT.gov ↗
What to watch
EnvafolimabPhase 2Solid Tumor
Est. primary completion 2027-08-30 · NCT04891198 · CT.gov ↗
What to watch
December 2027 (1)
EnvafolimabPhase 3Non-small Cell Lung Cancer
Est. primary completion 2027-12-30 · NCT06123754 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
EnvafolimabPhase 2Biliary Tract Neoplasms
Est. primary completion 2029-06 · NCT04910386 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.